Biotron Limited Stock

BIT

AU000000BIT4

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:07 2026-10-07 EDT			5-day change	1st Jan Change
0.002000 ^AUD	0.00%		0.00%	-33.33%

08-27	Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-26	Biotron Limited Auditor Raises 'Going Concern' Doubt	CI

Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The Company has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The Company also owns SedRx, which is a general anesthetic containing alfaxalone.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-07	A$0.002000	0.00%	6,245,336
26-10-06	A$0.002000	+100.00%	1,601,931
26-10-05	A$0.001000	-50.00%	2,760,148
26-10-02	A$0.002000	0.00%	1,968
26-10-01	A$0.002000	0.00%	1,598,224

Delayed Quote Australian S.E.

More quotes

As early as today, start finding the best investment opportunities!

Market Cap	5.57M 3.88M 3.46M 3.23M 2.94M 5.53M 375M 38.84M 15.17M 191M 14.56M 14.24M 613M	P/E 2025	-6.29x	P/E 2026	-4.1x
Enterprise Value	4.02M 2.8M 2.5M 2.33M 2.12M 3.99M 270M 28.01M 10.94M 138M 10.5M 10.27M 442M	EV / Sales 2025	0.95x	EV / Sales 2026	12.5x
Free-Float	73.16%	Yield 2025 *	-	Yield 2026	-

08-27	Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-26	Biotron Limited Auditor Raises 'Going Concern' Doubt	CI
04-09	Biotron Michael Hoy to retire as chairman	RE
04-09	Biotron Limited Announces Chairman Changes	CI
03-30	Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026	CI
02-26	Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-05	Biotron Limited Announces Retirement of Robert B. Thomas as Non-Executive Director, Effective February 6, 2026	CI
12-28	New Zealand Shares End Lower Amid Silver Reaching Record Highs; Bankers Investment Trust Reports Net Asset Value	MT
12-22	Biotron Limited Appoints Paul Kasian as Non-Executive Director, Effective 23 December 2025	CI
25-10-14	Biotron to raise A$2.5 mln through 2 tranche placement at A$0.003 per share	RE
25-10-12	Biotron requests trading halt pending material acquisition, capital raising announcement	RE
25-08-27	Biotron Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
25-08-26	Biotron Limited Auditor Raises 'Going Concern' Doubt	CI

22-05-01	Biotron : BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PU
21-11-24	BIOTRON : DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PU
21-11-22	Biotron : Chairman's Address and Presentation to AGM	PU
19-12-16	Biotron : 17 Dec 2019Exercise of Options Raise $5.8 Million & Appendix 2A	PU
19-12-04	Biotron : 5 Dec 2019Appendix 3Y – Change of Director’s Interest Notice	PU

3 months	-20.00%
Current year	-33.33%

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.12
5 years	0		0.12
10 years	0		0.44

Biotron Limited Stock

Stocks

BIT

AU000000BIT4

Biotechnology & Medical Research

Valuation: Biotron Limited

Chart: Biotron Limited

Latest news: Biotron Limited

Press Releases: Biotron Limited

Quotes and Performance

Price Extremes

Managers and Directors: Biotron Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Director	Title	Age	Since
Michael Medway BRD	Director/Board Member	-	2025-07-15
Paul Kasian CHM	Chairman	68	2026-05-30
Graeme Wald BRD	Director/Board Member	63	2026-03-29

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/28/24	Michelle Miller	Expiration	Chief Executive Officer	165,000	0.0183%
11/28/24	Robert Thomas	Expiration	Director	268,403	0.0297%
11/28/24	Michael Hoy	Expiration	Chairman	934,780	0.1036%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOTRON LIMITED	0.00%	0.00%	-33.33%	-98.18%	3.89M
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.69B
ARGENX SE	+0.46%	-1.16%	+23.36%	+79.34%	58.81B
LONZA GROUP AG	+0.17%	-1.16%	+3.59%	+34.55%	48.45B
REVOLUTION MEDICINES, INC.	+0.50%	-1.77%	+331.24%	+702.20%	42.84B
IQVIA HOLDINGS INC.	-0.72%	-4.04%	+25.90%	+29.94%	42.79B
BEONE MEDICINES AG	+0.34%	-0.34%	+5.66%	+109.35%	41.25B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.13B
WUXI BIOLOGICS (CAYMAN) INC.	-2.07%	+1.16%	+35.00%	+26.28%	30.28B
BIONTECH SE	-0.50%	-3.37%	-9.42%	-14.35%	24.05B
Average	+0.13%	-0.23%	+44.05%	+101.60%	39.43B
Weighted average by Cap.	+0.56%	-0.54%	+55.51%	+130.20%

	2025	2026
Net sales	1.81M 1.26M 1.13M 1.05M 956K 1.8M 122M 12.65M 4.94M 62.1M 4.74M 4.64M 200M	526K 366K 327K 305K 277K 522K 35.41M 3.67M 1.43M 18.01M 1.37M 1.34M 57.89M
Net income	-319K -222K -198K -185K -168K -316K -21.45M -2.22M -868K -10.91M -832K -814K -35.07M	-1.52M -1.06M -944K -881K -800K -1.51M -102M -10.59M -4.14M -51.99M -3.97M -3.88M -167M
Net Debt	-932K -648K -579K -541K -491K -925K -62.73M -6.5M -2.54M -31.9M -2.43M -2.38M -103M	-1.55M -1.08M -966K -902K -819K -1.54M -105M -10.83M -4.23M -53.21M -4.06M -3.97M -171M

Markets		Quality
Australian S.E.	BIT	Delayed
OTC Markets	BITRF	Delayed